Guerbet: First-half 2023 revenue
GUERBET First-half 2023 revenue Acceleration of activity Half-year revenue: €378.6 million, up +2.8% at CER1, with a strong acceleration of activity in Q2, at +6.7% Very dynamic sales in Asia (+...
- Supported exchanges /
- F /
- 4G8.F
Guerbet SA (4G8 F) stock market data APIs
€30.95
0(0%)
as of October 29, 2024
Price chart is built with Anychart
Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine, and Artirem, a gadoteric acid that acts as a contrast agent for MRI, as well as prefilled syringes, injectors, accessories, and consumables for MRI, CT, and Cath Lab. It also provides digital solutions, such as Contrast&Care, an injection management solution; Dose&Care, an X-ray dose management solution; and icobrain, a cloud-based AI solution to quantify disease-specific brain structures for acute and chronic neurological conditions on MR and CT, as well as OptiProtect services. In addition, the company provides products for interventional radiology, including Lipiodol ethyl esters of iodinated fatty acids of poppyseed oil; Vectorio, a mixing and injection system for conventional trans-arterial chemoembolization; Patent Blue V, a blue dye; Axessio, a peripheral micro guidewire; and SeQure and DraKon, which are microcatheters. Further, it offers Hydra Vision, a digital imaging system for urological, gastroenterological, and gynecological treatment, as well as planning and diagnostic procedures; and urology accessories and consumables. Guerbet SA was incorporated in 1926 and is headquartered in Villepinte, France.
Guerbet SA Financial Data Overview
| 30.95 | |
| 30.95 | |
| - | |
| 30.95 | |
| 30.95 | |
| 16.2633-39.4 | |
| 394 M | |
| 12.5813 | |
| 12 609 K | |
| 841 M | |
| 0.0153 | |
| 0.732 |
Our easy-to-use no-coding solutions help you get the data effortlessly:
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
General: {
Code:
'4G8',
Type:
'Common Stock',
Name:
'Guerbet SA',
Exchange:
'F',
CurrencyCode:
'EUR',
CurrencyName:
'Euro',
CurrencySymbol:
'€',
CountryName:
'Germany',
CountryISO:
'DE',
OpenFigi:
NULL,
ISIN:
'FR0000032526',
CIK:
NULL,
EmployerIdNumber:
NULL,
FiscalYearEnd:
'December',
IPODate:
NULL,
InternationalDomestic:
NULL,
Sector:
'Healthcare',
Industry:
'Medical Devices',
}
Guerbet SA Fundamental Data is available in our Financial Data APIs
- Net Revenue 841 M
- EBITDA 110 M
- Earnings Per Share 2.46
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Guerbet SA Earnings via APIs
- Latest Release 2024-10-24
- EPS/Forecast NaN
Get Guerbet SA End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Get Guerbet SA latest news via APIs
Guerbet: Guerbet wins PI-CAI Grand Challenge on detection of prostate cancer
GUERBET Guerbet wins PI-CAI Grand Challenge on detection of prostate cancer Villepinte, 17 July 2023: Guerbet (FR0000032526 GBT), a global specialist in contrast media and medical imaging solutions,...
Do you have any questions?
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
